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Abstract SIRT1, an ubiquitousNAD(?)-dependent deace-
tylase that plays a role in biological processes such as
longevity and stress response, is significantly activated in
response to reactive oxygen species (ROS) production.
Resveratrol (Resv), an important activator of SIRT1, has
been shown to exert major health benefits in diseases
associated with oxidative stress. In ischemia–reperfusion
(IR) injury, a major role has been attributed to the mitogen-
activated protein kinase (MAPK) pathway, which is
upregulated in response to a variety of stress stimuli,
including oxidative stress. In neonatal rat ventricular
cardiomyocytes subjected to simulated IR, the effect of
Resv-induced SIRT1 activation and the relationships with
the MAPK pathway were investigated. Resv-induced
SIRT1 overexpression protected cardiomyocytes from
oxidative injury, mitochondrial dysfunction, and cell death
induced by IR. For the first time, we demonstrate that
SIRT1 overexpression positively affects the MAPK path-
way—via Akt/ASK1 signaling—by reducing p38 and JNK
phosphorylation and increasing ERK phosphorylation.
These results reveal a new protective mechanism elicited
by Resv-induced SIRT1 activation in IR tissues and
suggest novel potential therapeutic targets to manage
IR-induced cardiac dysfunction.
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Abbreviations
ASK1 Apoptosis signal-regulating kinase 1
Bcl-xl B cell lymphoma-extra large
Bcl-2 B cell lymphoma-2
BODIPY Boron-dipyrromethene
Calcein-AM Calcein acetoxymethyl ester
DEVD Asp Glu Val Asp
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
EDTA Ethylenediaminetetraacetic acid
EIA Enzyme immunoassay
ELISA Enzyme-linked immunosorbent assay
ERK Extracellular signal-regulated kinase
FACS Fluorescence-activated cell sorting
FAM Fluorescein acetoxymethyl ester
FLICA Fluorochrome Inhibitor of caspases
FMK Fluoromethyl ketone
FOXO1 Forkhead box O1
H2DCFDA 2
0, 70-Dichlorofluorescein diacetate
JNK Jun N-terminal kinase
LDH Lactate dehydrogenase
MAPK Mitogen-activated protein kinase
MnSOD Manganese superoxide dismutase
mPTP Mitochondrial permeability
transition pore
PAGE Polyacrylamide gel electrophoresis
PBS Buffered saline solution
PMSF Phenylmethanesulphonylfluoride
PVDF Polyvinylidene fluoride
ROS Reactive oxygen species
Resv Resveratrol
SD Standard deviation
SDS Sodium dodecyl sulphate
SIRT1 Sirtuin (Silent information regulator 2) 1
TAC Total antioxidant capacity
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TMRM Tetramethylrhodamine, methyl ester,
perchlorate
Trx1 Thioredoxin-1
UV Ultraviolet
Dw Mitochondrial membrane potential
Introduction
In heart, ischemia–reperfusion (IR) has been found to be a
major cause of myocyte necrosis and apoptosis. Such
processes appear to be the prevalent mode of cell death
during the ischemic and the reperfusion phases, respec-
tively. It is widely accepted that the oxidative stress, due to
an excessive production of reactive oxygen species (ROS),
is a prominent factor in triggering the events that ultimately
result in cardiomyocyte death [1, 2]. The intracellular
signaling pathways that lead to this effect, however, are
relatively poorly understood. A mechanism for cardiomy-
ocyte death during IR has been related to the stress
responsive members of the mitogen-activated protein
kinase (MAPK) family. A variety of stress stimuli,
including oxidative stress, induces functional changes of
these kinases, similar to those found associated with
apoptosis [3]. A recent finding suggests that cardiac SIRT1,
a mammalian ortholog of Silent information regulator 2
(Sir2) family, is significantly upregulated in response to
oxidative stress [4]. The members of the Sir2 family, a
group of highly conserved proteins showing NAD-depen-
dent histone deacetylase activity, have been indicated as
modulators of the life-span in many living species. Some
reports suggested that mammalian sirtuins may play a role
in DNA repair [5]. An early finding that pointed to a role
for Sir2 as a life-span regulator in yeast was later confirmed
for SIRT1 [6]. However, increasing evidence suggests that,
in mammals, sirtuins may affect the aging process by
regulating several processes, such as glucose homeostasis,
insulin secretion, fat metabolism, and resistance to stress
[7, 8]. SIRT1 was initially thought to be localized exclu-
sively in the cell nucleus; however, recent evidence
suggests that the protein shuttles between the nucleus and
the cytosol, making it possible to play functions in the
cytosolic milieu [9]. SIRT1 targets multiple proteins
involved in apoptosis, including p53, p73, E2F, HIC1, and
Ku70, and modulates cell survival by regulating the
Forkhead family of transcription factors (FOXOs). Acting
via FOXO4, SIRT1 also suppresses caspase-3 and caspase-
7 in transformed cells, but not in normal cells [10]. Inter-
estingly, caspase-9 and Bcl-xL regulate SIRT1 cleavage
during apoptosis, causing it to relocalize from the nucleus
to the cytosol [11]. A number of recent reports have sought
to elucidate the direct effects of SIRT1 in mammalian
tissues. Moderate expression levels of SIRT1 have been
shown to slow coronary aging and promote resistance to
oxidative stress and apoptosis, suggesting that SIRT1
protects the heart from in vivo stress [4]. In any case, the
data currently available in the literature indicating a variety
of effects on cellular metabolism and gene expression
suggest sirtuins play a role in cardioprotection, as over-
expression of SIRT1 protects cardiomyocytes from serum
deprivation-induced cell death and promote an increase in
cell size [12]. In contrast, sirtuin inhibition triggered cell
death in isolated neonatal rat cardiomyocytes [13].
Trans-resveratrol (trans-3,40,5-trihydroxystilbene, Resv),
a polyphenol of red wine, is one of the substances proposed
to be responsible for the prevention of cardiovascular dis-
ease, especially in coronary artery disease. Resv reportedly
protects the heart from ischemic-reperfusion injury [14].
With regard to cardiomyoblasts, it has been suggested that
Resv has direct beneficial effects against ischemia/hypoxia
of cardiomyocytes, protecting these cells from apoptosis
through the involvement of SIRT1 [15].
The present study aims to assess whether SIRT1 has an
effective role in protecting cardiac cells from IR injury and
to explore the involvement of this protein in the modulation
of typical redox-sensitive MAPKs such as JNK (c-Jun NH2
terminal kinase), ERK (extracellular signal-regulated
kinase) and p38. Our results add novel insights to this
contentious field.
Materials and methods
Cell cultures
Primary neonatal rat ventricular cardiomyocytes (R-CM-
561) from Lonza (Lonza Walkersville, Inc. Walkersville,
MD, USA) were plated at a density of 8 9 105/100 mm
plate and cultured, at 37°C in a 5% CO2 humidified
atmosphere, in CloneticsÒ RCGM Rat Cardiac Myocyte
Growth Medium. Resv, Trolox, 6-chloro-2,3,4,9-tetra-
hydro-1H-carbazole-1-carboxamide (SIRT1 inhibitor),
SB203580 (p38 kinase inhibitor), and PD98059 (MEK
inhibitor), SP600125 (JNK inhibitor) were all purchased
from Sigma (Sigma-Aldrich Co., St. Louis, MO). All other
reagents were of the highest purity available.
Simulation of IR (ischemia–reperfusion)
Simulated IR was achieved using a modular incubator
chamber (Billups-Rothenberg Inc., Del Mar, CA, USA),
gassed with 95% NO2 and 5% CO2. A flow meter was used
to measure the quantity of gas mixture introduced into the
chamber (25 l/min), as shown by Namiki et al. [16]. To
simulate IR, cells that had been incubated under conditions
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of hypoxia in serum and in glucose-free medium for 5 h
were reoxygenated by replacing the culture medium, and
were returned to a normoxic environment at 37°C for
60 min. Cells were treated 24 h prior to hypoxic challenge
by adding Resv or TroloxÒ at concentrations of 20 and
15 lM, respectively, which we found to display the same
antioxidant capacity (see below). To check for possible
toxic effects of these compounds, the normoxic control
cardiomyocytes were also subjected to the same treatments.
In another set of experiments, designed to determine the
relative importance of ERK, p38 and JNK signaling path-
ways in this experimental model, cells were treated with
10 lM SB203580 (p38 kinase inhibitor), 10 lM SP600125
(JNK inhibitor) or 10 lM PD98059 (MEK inhibitor) for
1 h prior to hypoxia. In another set of experiments, 1 lM
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
(specific SIRT1 inhibitor) was added to the culture medium
for 1 h prior to hypoxia.
Preparation of cell lysates
Cardiomyocytes were washed twice with phosphate buf-
fered saline (PBS), trypsinized, centrifuged, and then
resuspended in 100 ll of lysis buffer containing 1% Triton
X-100, 20 mM Tris–HCl pH 8, 137 mM NaCl, 10% (v/v)
glycerol, 2 mM EDTA, and 6 M urea supplemented with
0.2 mM PMSF, 10 lg/ml leupeptin, and aprotinin. To
obtain cell lysates after three freeze–thaw cycles, cells
were twice sonicated in ice for 5 s and then centrifuged at
14,000 9 g for 10 min at 4°C. The supernatant was
retained and protein concentration determined according to
the Bradford method [17].
Measurement of lactate dehydrogenase release
Lactate dehydrogenase (LDH) activity, a marker of cell
death, was assessed spectrophotometrically in culture
medium and in adherent cells (in order to determine total
LDH activity) using the LDH assay kit (Roche Diagnostics,
Mannheim, Germany). LDH release was calculated as a
percentage of total LDH content. In another set of exper-
iments, designed to determine the relative importance of
ERK, p38 and JNK signaling pathways in this experimental
model, cells were treated with 10 lM SP600125 (specific
JNK inhibitor), 10 lM PD98059 (MEK inhibitor) or 1 lM
6-Chloro-2,3,4,9-tetrahydro-1H-Carbazole-1-carboxamide
(SIRT1 inhibitor) for 1 h prior to hypoxia.
Western-blot analysis of SIRT1, p-ASK1, p-ERK,
and p-p38
To assess the levels of SIRT1, phosphorylated ERK
(p-ERK) and phosphorylated p38 (p-p38), equal amounts
of cell lysates (40 lg for ERK1, p-ERK and SIRT1, 60 lg
for p38 and p-p38) were diluted in Laemmli sample buffer,
boiled for 5 min and separated on pre-cast 4–12% SDS-
PAGE gels (Criterion XT, Bio-Rad, Hercules, CA). Pro-
teins were blotted onto PVDF Hybond membranes, which
were then incubated overnight at 4°C with (rabbit) anti-p-
ASK1 pSer83 antibody (GenWay Biotech, Inc., San Diego,
CA) (rabbit) anti-ASK1 (rabbit) anti-SIRT1 (rabbit) anti-
ERK 1 (mouse) anti-p- ERK, (mouse) anti-p38 and
(mouse) anti-p-p38 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA). After washing, the membranes were incubated
with peroxidase-conjugated secondary antibodies for 1 h.
Immunolabeled bands were detected using a supersignal
west dura (Pierce, Rockford, IL, USA) and quantified using
the aforementioned software for image analysis. Results
were expressed as densitometric ratios between the protein
of interest and the loading control (b-actin).
Immunoprecipitation and immunoblot analysis
For immunoprecipitation, whole cell lysates were pre-
cleared with Protein A/G plus (Santa Cruz Biotechnology
Inc.) for 30 min at 4°C. Beads were pelleted at 1,000 9
g for 30 s and pre-cleared supernatants were incubated
with 15 lg of primary antibody-agarose conjugates at 4°C
overnight on a rotator. When agarose or a gel conjugate
was unavailable, lysates were incubated with anti-Akt
antibody (Santa Cruz Biotechnology Inc.) for 2 h at 4°C
and then overnight along with Protein A/G plus beads to
collect the immune complexes. Beads were collected by
centrifugation, washed several times with RIPA buffer, one
wash with PBS, and resuspended in SDS-PAGE sample
loading buffer. Immune complexes and 80 lg of proteins
were resolved by SDS-PAGE. Proteins were blotted onto
PVDF Hybond membranes, which were then incubated
overnight at 4°C with (mouse) anti-Akt antibody, (mouse)
anti-pAkt (mouse) anti-Ac-lysine (Santa Cruz Biotechnol-
ogy Inc.). After washing, the membranes were incubated
with peroxidase-conjugated secondary antibodies for 1 h.
Immunolabeled bands were detected using a supersignal
west dura (Pierce, Rockford, IL, USA).
JNK levels
Cardiomyocytes were plated in 96-well culture plates and
then subjected to the aforementioned procedure. After
fixing cells in 4% formaldehyde (resuspended in PBS),
total JNK and phosphorylated JNK were quantified using a
commercially available assay (JNK ELISA kit; FACE,
Active Motif Europe, Rixensart, Belgium), following the
manufacturer’s instructions.
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Determination of intracellular ROS and mitochondrial
superoxide
Cells were seeded on glass cover slips and loaded with
the mitochondrial superoxide-specific fluorescent probe
MitoSOX (3 lM) and H2DCFDA (2.5 lM) (Invitrogen,
CA, USA)—dissolved in 0.1% DMSO and pluronic acid
F-127 (0.01% w/v), which was added to the cell culture
media for 15 min at 37°C. Cells were fixed in 2.0% buffered
paraformaldehyde for 10 min at room temperature and
MitoSOX fluorescence analyzed (at an excitation wave-
length of 514 nm) using a Leica TCS SP5 confocal scanning
microscope (Leica, Mannheim, Germany) equipped with an
argon laser for fluorescence analysis. A series of optical
sections (1024 9 1024 pixels) 1.0 lm in thickness was
taken through the cell depth at intervals of 0.5 lm using a
Leica 209 objective and then projected as a single com-
posite image by superimposition.
H2DCFDA fluorescence were analyzed (at an excitation
wavelength of 488 nm) using a Leica TCS SP5 confocal
scanning microscope (Mannheim, Germany) equipped with
an argon laser for fluorescence analysis. A series of optical
sections (1024 9 1024 pixels) 1.0 lm in thickness was
taken through the cell depth at intervals of 0.5 lm using a
Leica plan apo 639 oil immersion objective and then
projected as a single composite image by superimposition.
ROS generation was also monitored by flow cytometry:
single-cell suspensions were incubated with H2DCFDA
(1 lM) (Invitrogen) for 15 min at 37°C and immediately
analyzed.
Total antioxidant capacity (TAC)
Intracellular TAC, which accounts for ROS scavengers,
was measured in cell lysates by chemiluminescent assay
using the photoprotein Pholasin (Abel Antioxidant Test
Kit, Knight Scientific Limited, Plymouth, UK), following
the manufacturer’s instructions. Protein content in the
soluble fraction was measured using the Bradford method
[17] and results were calculated using an L-ascorbic-acid-
based standard curve.
Evaluation of lipid peroxidation
To assess the rate of lipid peroxidation, isoprostane levels
were measured in cell lysates using the 8-isoprostane EIA
kit (Cayman Chemical Co., Ann Arbor, MI, USA), fol-
lowing the manufacturer’s instructions. Lipid peroxidation
was also investigated by confocal scanning microscopy
using BODIPY, a fluorescent probe that is intrinsically
lipophilic and thus mimics the properties of natural lipids
[18]. BODIPY 581/591 C11 acts as a fluorescent lipid
peroxidation reporter that shifts its fluorescence from red to
green in the presence of oxidizing agents. Briefly, cells
were cultured on glass cover slips and loaded with dye by
adding the fluorescent probe BODIPY, dissolved in 0.1%
DMSO (5 mM final concentration), to the cell culture
media for 30 min at 37°C. The cells were fixed in 2.0%
buffered paraformaldehyde for 10 min at room temperature
and the BODIPY fluorescence was analyzed (at an exci-
tation wavelength of 581 nm) using a confocal Leica TCS
SP5 scanning microscope (Mannheim, Germany) equipped
with an argon laser source for fluorescence measurements.
A series of optical sections (1024 9 1024 pixels) 1.0 lm
in thickness was taken through the cell depth at intervals of
0.5 lm using a Leica plan apo 639 oil immersion objec-
tive and then projected as a single composite image by
superimposition. Moreover, lipid peroxidation was quan-
tified by flow cytometry. Single-cell suspensions were
washed twice with PBS and incubated, in the dark, for
30 min at 37°C with BODIPY 581/591 (2 mM) in DMEM.
After labeling, cells were washed and resuspended in PBS
and analyzed using a FACSCanto flow cytometer (Becton-
Dickinson, San Jose, CA, USA).
Mitochondrial number
Mitochondrial number was determined using mitotracker
deep red 633 (Invitrogen), which was used to stain mito-
chondria, and confocal microscopy used to visualize
individual mitochondria. Briefly, cells were seeded on
glass cover slips and loaded with mitotracker deep red 633
fluorescent probe (0.5 lM)—dissolved in 0.1% DMSO and
pluronic acid F-127 (0.01% w/v), which was added to cell
culture media for 20 min at 37°C. Cells were fixed in 2.0%
buffered paraformaldehyde for 10 min at room temperature
and red fluorescence analyzed (at an excitation wavelength
of 633 nm) using a Leica TCS SP5 confocal scanning
microscope (Mannheim, Germany) equipped with an argon
laser source for fluorescence analysis. Mitochondrial
number was also monitored by flow cytometry. Single-cell
suspensions were incubated with mitotracker deep red 633
(200 nM) for 20 min at 37°C and immediately analyzed by
flow cytometry.
Mitochondrial permeability transition pore opening
Mitochondrial permeability was analyzed using the fluo-
rescent calcein-AM probe, according to the method
described by Petronilli et al. [19], albeit with minor mod-
ifications. Calcein-AM freely enters cells and emits
fluorescence upon de-esterification. Co-loading of cells
with cobalt chloride quenches cell fluorescence except in
mitochondria. This is because cobalt cannot cross mito-
chondrial membranes (living cells). During mitochondrial
permeability transition pore opening (mPTP), cobalt can
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enter mitochondria and is able to quench calcein fluores-
cence (apoptotic cells). Thus, decreased mitochondrial
calcein fluorescence can be considered a measure of the
extent of mPTP induction. Briefly, single-cell suspensions
were incubated with the fluorescent probes calcein-AM
(Invitrogen) (3 lM) and cobalt chloride (1 mM) for 20 min
at 37°C, washed twice with PBS and analyzed using a
FACSCanto flow cytometer (Becton-Dickinson, San Jose,
CA, USA).
Assessment of caspase activity by FACS analysis
Caspase-3 and caspase-9 activity was analyzed by flow
cytometry. In brief, single-cell suspensions were incubated
with FAM-FLICA
TM
Caspases solution (Caspase FLICA kit
FAM-DEVD-FMK) for 1 h at 37°C, washed twice with
PBS and analyzed using a FACSCanto flow cytometer
(Becton-Dickinson). In another set of experiments,
designed to determine the relative importance of ERK, p38
and JNK signaling pathways in this experimental model,
cells were treated with 10 lM SP600125 (specific JNK
inhibitor), 10 lM PD98059 (MEK inhibitor) or 1 lM
SIRT1 inhibitor for 1 h prior to hypoxia.
Mitochondrial membrane potential
Mitochondrial membrane potential was assessed using
tetramethylrhodamine methyl ester perchlorate (TMRM)
(Invitrogen). TMRM is a lipophilic potentiometric dye that
partitions between the mitochondria and cytosol in pro-
portion to mitochondrial membrane potential (Dw), by
virtue of its positive charge. At low concentrations, fluo-
rescence intensity is a function of dye concentration, which
is in turn a direct function of mitochondrial potential.
Therefore, the accumulation of dye in mitochondria and the
intensity of the signal is a direct function of mitochondrial
potential. Mitochondrial membrane potential was also
quantified by flow cytometry. Single-cell suspensions were
washed twice with PBS and then incubated, in the dark, for
20 min at 37°C with TMRM (100 nm) resuspended in
DMEM. After labeling, the cells were washed and resus-
pended in PBS, and analyzed using a FACSCanto flow
cytometer.
Determination of cellular SIRT1 activity
Cellular SIRT1 activity was determined according to the
method described by Fulco et al. [20] with some modifi-
cations. Cell extracts were obtained by using a lysis buffer
(50 mM Tris–HCl pH 8, 125 mM NaCl, 1 mM DTT,
5 mM MgCl2, 1 mM EDTA, 10% glycerol, and 0.1%
NP40 supplemented with 1 mM PMSF and protease
inhibitors mix) and SIRT1 activities were determined by
SIRT1 direct fluorescent screening assay kit (Cayman, Ann
Arbor, MI). A total of 25 ll of assay buffer (50 mM Tris–
HCl, pH 8.0, containing 137 mM NaCl, 2.7 mM Kcl, and
1 mM MgCl2), 5 ll of extracts, and 15 ll of substrate
solution were added to all wells. The plate was incubated
on a shaker for 45 min; 50 ll of stop/development solution
was added to each well and incubated for 30 min at room
temperature. The fluorescence of the plate was then
determined using a Perkin-Elmer LS 55 luminescence
spectrometer using as excitation wavelength of 360 nm and
an emission wavelength of 460 nm.
Statistical analysis
All data is expressed as mean ± SD. Comparisons between
different groups were carried out using the one-way anal-
ysis of variance (ANOVA) followed by Bonferroni t test. A
p value of\0.05 was accepted as statistically significant.
Results
Dose-dependent effects of Resv on SIRT1 expression
and activity
As a preliminary test aimed at evaluating the effect of Resv
on SIRT1 expression, dose-dependent Western-blot anal-
ysis of cell lysates was carried out in the presence of
increasing Resv concentrations (from 2.5 lM to 40 lM).
Cardiomyocytes subjected to 24 h-treatment with 20 lM
Resv displayed a 3.5-fold increase in SIRT1 expression
(Fig. 1a). We also tested the effect of Resv in modulating
SIRT1 activity in the presence of the same increasing Resv
concentrations. Cardiomyocytes subjected to 24-h treat-
ment with 20 lM Resv displayed a fourfold increase in
SIRT1 activity (Fig. 1b).
Effects of Resv and Trolox on control cells
In order to verify the possible direct effect of Resv and
Trolox on the considered parameters, independent of IR
conditions, these substances were added, at the same con-
centrations used to treat IR cells, to control normoxic
neonatal rat ventricular cardiomyocytes. No significant
changes were observed in control cells, except for expected
increases in TAC, exerted by the two antioxidants
(Table 1) and in SIRT1 expression, displayed by Resv
(Fig. 3). SB203580, SP600125, and SIRT1 inhibitor, when
added to control cells at the same concentration used dur-
ing experiments, caused no toxic effects (data not shown).
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Oxidative stress markers and antioxidant protection
of SIRT1 overexpression in neonatal cardiomyocytes
subjected to simulated IR
To investigate the effect of SIRT1 overexpression, neonatal
rat ventricular cardiomyocytes were grown for 24 h in the
presence of 20 lM Resv. To see whether the effects of
Resv were due to its antioxidant activity only, experiments
were also performed in the same cells treated with 15 lM
Trolox, a concentration required to obtain the same anti-
oxidant capacity (assayed as above described) of 20 lM
Resv. TAC and lipoperoxidation markers (8-isoprostane
levels and BODIPY fluorescence) were measured in these
cells (Table 1; Fig. 2d). Compared to controls, IR cells
exhibited marked reduction in TAC and a significant
increase in the concentration of 8-isoprostanes confirming
the results of our previous investigation [21]. All cells
treated with Resv and Trolox (both without and with IR)
displayed significantly higher TAC with respect to corre-
sponding untreated cells (p\ 0.05); treatment with Resv
caused a significant increase in cellular TAC after IR
injury, more so than Trolox. As with the increased TAC,
the concentration of 8-isoprostanes was much lower in
Resv-treated IR cells compared to Trolox-treated IR cells
(p\ 0.05). ROS production was investigated by FACS and
confocal microscopy analysis using the fluorescent probe
H2DCFDA (Fig. 2a, b). IR cells produced intense fluores-
cent signals, indicating a strong and significant increase in
ROS production. Resv- and Trolox-treated IR cells were
characterized by less-marked fluorescence, demonstrating a
strong protective effect of these compounds against ROS
production. Similar results were obtained evaluating
mitochondrial superoxide production by confocal micro-
scope analysis (Fig. 2c). Resv again proved to be more
protective than Trolox. In the presence of SIRT1 inhibitor,
the intensity of ROS production did not differ significantly
from untreated IR cardiomyocytes.
SIRT1 expression and activity in IR cardiomyocytes
The effect of Resv on SIRT1 expression and activity under
conditions of oxidative stress were investigated. As shown
in Fig. 3a, when cells were subjected to simulated IR the
expression of endogenous SIRT1 was only slightly, but
significantly, increased (?25% vs. control, p\ 0.05).
Interestingly, pre-treating with Resv upregulated SIRT1
expression (?150% vs. control, p\ 0.05): similar pre-
treatment with Trolox did not, however (NS vs. control).
However, a significant decrease in SIRT1 expression was
observed upon addition of a SIRT1 inhibitor to Resv-pre-
treated cells (p\ 0.05 vs. control, p\ 0.05 vs. IR). Also,
as shown in Fig. 3b, SIRT1 activity was significantly
increased in IR condition (?50% vs. control, p\ 0.05) and
pre-treating with Resv upregulated SIRT1 activity (?300%
vs. control, p\ 0.05). Trolox treatment did not affect
SIRT1 activity in IR condition.
Resv-induced SIRT1 overexpression protects
cardiomyocytes from IR-induced necrosis
and apoptosis
Necrotic cell death in IR neonatal rat cardiomyocytes was
assessed by measuring LDH release (LDH released/total
LDH). Our results (Fig. 4a) show that IR induced about
ten-fold increase in cell death compared to control cells
(p\ 0.05). Trolox treatment triggered a significant
decrease in the rate of cell death (-28% vs. IR, p\ 0.05).
An even more protective effect was exerted by Resv,
which, compared to IR cells, reduced cell death by half
(p\ 0.05 vs. IR, p\ 0.05 vs. Trolox). Interestingly, cells
treated with both Resv and a SIRT1 inhibitor displayed
higher levels of cell death to those observed in IR cells
(p\ 0.05 vs. IR).
Fig. 1 SIRT1 expression (a) and activity (b) in neonatal rat
ventricular cardiomyocytes after 24 h of incubation with different
concentrations of Resv. In Western-blot analysis, all signals were
quantified by densitometric analysis and are expressed as ratio of
SIRT1 densitometry on b-actin (loading control) densitometry.
*Significant difference (p B 0.05) versus untreated cells. The
reported values (mean ± SD) are representative of four independent
experiments, each performed in triplicate
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Caspase-3 and -9 activities were measured to confirm
that apoptosis occurs under our experimental conditions
and to explore a potential correlation with SIRT1 activa-
tion. As shown in (Fig. 4b, c) an increase in caspase-3 and
caspase-9 activities was seen in ischemic cells following
1 h of reperfusion (both caspase-3 and caspase-9 activities
were about fourfold higher compared to controls;
p\ 0.05). This increase was reversed by Resv pre-treat-
ment prior to ischemic challenge (both for caspase-3 and
caspase-9, Resv vs. IR p\ 0.05). Trolox, albeit to a lesser
Table 1 Redox status in neonatal rat ventricular cardiomyocytes
Total antioxidant capacity ascorbate
equivalent unit (nmol/mg of protein)
8-Isoprostanes
(pg/mg of protein)
Control 14.01 ± 1.52 55.42 ± 5.61
Control ? Trolox 21.70 ± 2.01* 59.04 ± 6.21
Control ? resveratrol 22.54 ± 2.13* 51.80 ± 5.43
Control ? resveratrol ? SIRT1 inhibitor 9.48 ± 0.80* 49.43 ± 5.65
IR 10.46 ± 0.93* 244.58 ± 15.30*
IR ? Trolox 14.18 ± 1.04# 132.53 ± 11.75*#
IR ? resveratrol 21.44 ± 2.34*# 81.95 ± 7.29*#
IR ? resveratrol ? SIRT1 inhibitor 10.9 ± 1.21* 208.41 ± 22.14*#
Cellular TAC (total antioxidant capacity) and lipid peroxidation levels (8-isoprostanes) measured in the cytosolic fractions of neonatal rat
ventricular cardiomyocytes
* Significant difference (p B 0.05) versus control (C) cells. #Significant difference (p B 0.05) versus IR cells
Fig. 2 a FACS analysis of ROS production by H2DCFDA fluores-
cence in control normoxic (C) and in IR neonatal rat ventricular
cardiomyocytes in the presence of Resv (R), Trolox (T), or SIRT1
inhibitor (I). *Significant difference (p B 0.05) versus control
(C) cells. #Significant difference (p B 0.05) versus IR cells.
b Confocal microscope analysis of ROS production (639 magnifi-
cation). c Mitochondrial superoxide (209 magnification), and
d lipoperoxidation (639 magnification) in IR neonatal rat ventricular
cardiomyocytes. The reported values (mean ± SD) are representative
of five independent experiments, each performed in triplicate
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extent, significantly reduced apoptosis (both for caspase-3
and caspase-9 Trolox vs. IR p\ 0.05). In any case, a
significant difference (p\ 0.05) was observed between
Resv and Trolox treatments, both for caspase-3 and cas-
pase-9. In IR cells, a significant increase in caspase-3 and
-9 activities was evident when SIRT1 inhibitor was added
to the reaction medium.
To further investigate the observed protective effect, we
explored, in IR cardiomyocytes, in the presence of Resv,
Trolox or Resv and SIRT1 inhibitor, mitochondrial depo-
larization and mitochondrial permeability transition pore
opening (Fig. 5a, b), which are usually considered markers
of cell suffering and apoptosis.
As expected, simulated IR strongly impaired mito-
chondrial depolarization (Fig. 5a), which was restored
upon Resv treatment (p\ 0.05 vs. untreated IR), and to a
lesser extent by Trolox (p\ 0.05 vs. untreated IR).
Treating IR cells with both Resv and SIRT1 inhibitor did
not cause any significant change compared to untreated IR
cells. Similar effects were observed when assessing mito-
chondrial permeability transition pore opening (Fig. 5b),
which was markedly affected by IR and efficiently restored
by Resv treatment only (p\ 0.05 vs. untreated IR).
Mitochondrial number can influence experiments where
mitochondrial function is investigated; we therefore coun-
ted the number of mitochondria in Resv-treated or not-
treated neonatal cardiomyocytes to ensure that increased
mitochondrial function was not due to increased mito-
chondrial number. In our experimental conditions, there
was no significant increase in mitochondrial number upon
Resv treatment (data not shown). Therefore, the observed
Fig. 3 SIRT1 expression a and activity b in IR neonatal rat
ventricular cardiomyocytes. In western blot analysis all signals were
quantified by densitometric analysis and were expressed as a ratio of
SIRT1 densitometry versus b-actin (loading control) densitometry.
*Significant difference (p B 0.05) versus untreated cells. #Significant
difference (p B 0.05) versus IR cells. Control normoxic cells (C),
Resv (R), Trolox (T), SIRT1 inhibitor (I). The reported values
(mean ± SD) are representative of four independent experiments,
each performed in triplicate
Fig. 4 a Release of cellular LDH into the culture media measured by
spectrofluorimetric analysis, b the caspase-3, and c caspase-9
activities measured by flow cytometry assayed in IR neonatal rat
ventricular cardiomyocytes. *Significant difference (p B 0.05) versus
control cells. #Significant difference (p B 0.05) versus IR cells.
Control normoxic cells (C), Resv (R), Trolox (T), SIRT1 inhibitor (I).
The reported values (mean ± SD) are representative of four inde-
pendent experiments, each performed in triplicate
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changes in mitochondrial function and cell viability were
not due to changes in mitochondrial number.
MAPK pathways are affected by Resv treatment in IR
cardiomyocytes
As shown previously, neonatal cardiomyocytes subjected
to simulated IR showed signs of oxidative stress and cell
death. To investigate the pathways involved in cell dam-
age, we examined p38, ERK, and JNK activation, all of
which are regulated by redox status. Under our experi-
mental conditions, simulated IR induced an almost twofold
increase in the p-p38/total p38 ratio (Fig. 6a) (p\ 0.05 vs.
control), p38 being an enzyme whose activation is asso-
ciated with the triggering of apoptosis. Resv treatment
reduced p38 phosphorylation to control levels (NS vs.
control, p\ 0.05 vs. IR). Treatment with Trolox or with
Resv ? SIRT1 inhibitor did not lead to a similar reduction
in p-38 phosphorylation (NS vs. IR).
The levels of JNK phosphorylation are shown in Fig. 6b.
Simulated IR led to an increase in the p-JNK/total JNK
ratio, which was significant compared to controls
(p\ 0.05). As already observed, Resv significantly
decreased the entity of JNK phosphorylation (p\ 0.05 vs.
IR).
Figure 6c shows the levels of ERK phosphorylation,
whose anti-apoptotic effect is well documented. In this
case, simulated IR lead to a significant reduction in the
Fig. 5 a Mitochondrial depolarization and b mitochondrial perme-
ability transition pore opening measured by flow cytometry in IR
neonatal rat ventricular cardiomyocytes. *Significant difference
(p B 0.05) versus control cells. #Significant difference (p B 0.05)
versus IR cells. Control normoxic cells (C), Resv (R), Trolox (T),
SIRT1 inhibitor (I). The reported values (mean ± SD) are represen-
tative of four independent experiments, each performed in triplicate
Fig. 6 MAPK phosphorylation in IR neonatal rat ventricular cardio-
myocytes. a Western-blot analysis of phosphorylated p38 expression.
All signals were quantified by densitometric analysis and were
expressed as a ratio of p-p38 densitometry versus total p38 (loading
control) densitometry. b Quantification of total and phosphorylated
c-Jun N-terminal kinase by ELISA. c Western-blot analysis of
phosphorylated ERK expression. All signals were quantified by
densitometric analysis and were expressed as a ratio of p-ERK
densitometry versus total ERK (loading control) densitometry.
*Significant difference (p B 0.05) versus control cells. #Significant
difference (p B 0.05) versus IR cells. Control normoxic cells (C),
Resv (R), Trolox (T), SIRT1 inhibitor (I). The reported values
(mean ± SD) are representative of four independent experiments,
each performed in triplicate
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p-ERK/total ERK ratio, which was reversed by Resv
treatment only (p\ 0.05 vs. IR).
To probe the possible relationships between SIRT1 and
MAPK pathways in IR, we analyzed caspase-3 activity and
LDH release in the presence of specific MAPK and SIRT1
inhibitors. As previously described, IR triggered a marked
increase (p\ 0.05 vs. control) in caspase-3 activity
(Fig. 7a). Pre-treating cells with Trolox or Resv caused a
sharp reduction in caspase-3 activation (p\ 0.05 vs.
untreated IR). When SIRT1 inhibitor was used, caspase-3
activity rose to values similar to those seen in untreated IR
cells (NS vs. IR). In the presence of p38 or JNK inhibitor
(p38i or JNKi, respectively), levels of apoptosis signifi-
cantly decreased (p\ 0.05 vs. untreated IR), suggesting
the involvement of these pathways in IR-induced cell
death. When Resv was added along with these inhibitors,
caspase-3 activity further decreased (p\ 0.05 vs.
IR ? p38i or JNKi). The presence of SIRT1 inhibitor
together with p38i or JNKi triggered an increase in cas-
pase-3 activity (NS vs. IR ? p38i or JNKi). Interestingly,
IR cells displayed the greatest caspase-3 activity in the
presence of ERK inhibitor. Caspase-3 activity was unaf-
fected by other treatments, thus suggesting a prominent
role for ERK in protection against apoptotic cell death.
When LDH release was assayed in the presence of anti-
oxidants and p38, JNK, and ERK inhibitors (Fig. 7b),
maximum LDH release was again observed in the presence
of the ERK inhibitor. Pre-treatment with p38 and JNK
inhibitors clearly protected against cell death, as shown by
the decrease in LDH release. Simultaneous treatment with
the three inhibitors did not protect against cell death (data
not shown). When antioxidants were added along with p38
or JNK inhibitor, treatment with Trolox led to a mild
decrease in LDH. The decrease in LDH release was more
marked following treatment with Resv, however, indicat-
ing greater protection against cell death. In the presence of
ERK, inhibitor antioxidants did not protect against necrotic
cell death, indicating a crucial role for this pathway in
preventing IR-induced cell death.
SIRT1 deacetylases Akt and inhibits ASK1 activation
To identify the potential intermediates between SIRT1 and
MAPKs pathways, we examined Akt (protein kinase B)
and apoptosis signal-regulating kinase 1 (ASK1) that acts
upstream of JNK and p38 kinases [22, 23]. Deacetylation
of lysine residues is a posttranslational mechanism that
controls the activity of many cellular proteins, including
kinases. It has been shown that SIRT1 activate Akt and that
Akt can phosphorylate ASK1 at Ser-83 to maintain ASK1
in an inactive form [24]. Akt immunoprecipitates from
cardiomyocytes indicated that phosphorylation of Akt
was enhanced in Resv-treated cells, findings that were
associated with Akt deacetylation, indicating that SIRT1
deacetylates and activates Akt (Fig. 8a). Interestingly, when
SIRT1 inhibitor was used, deacetylation and phosphoryla-
tion level of Akt decreased to values similar to those seen in
untreated IR cells, demonstrating that SIRT1 is necessary
for Akt activation. Furthermore, phosphorylation level at
Ser-83 of ASK1 (a specific Akt phosphorylation site) was
high in Resv-treated cardiomyocytes indicating that Akt can
inactivate ASK1 via SIRT1 pathways (Fig. 8b). When
SIRT1 inhibitor was added, ASK1 phosphorylation level at
Ser-83 greatly decreased.
Discussion
Myocardial IR injury is an important cause of organ
damage. Reperfusion triggers a series of adverse events
that culminate in contractile dysfunction, endothelial dys-
function, and cell death [25, 26]. There are currently no
drugs for clinical use to reduce reperfusion injury, indeed,
the pathways implicated in IR injury are the subject of
intense research.
In the present study, neonatal rat cardiomyocytes, sub-
jected to simulated IR, exhibited marked biochemical
changes, including clear signs of oxidative stress (increase
Fig. 7 a Caspase-3 activity measured using flow cytometry and b the
release of cellular LDH into the culture media assayed in IR neonatal
rat ventricular cardiomyocytes in the presence of specific MAPK
inhibitors. *Significant difference (p B 0.05) versus control cells.
#Significant difference (p B 0.05) versus IR cells. Control normoxic
cells (C), Resv (R), Trolox (T), SIRT1 inhibitor (I). The reported
values (mean ± SD) are representative of four independent experi-
ments, each performed in triplicate
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in ROS production and in lipoperoxidation markers) and
cell death (both apoptosis and necrosis). Mitochondrial
dysfunction appeared to play a prominent role in ROS
production and in the onset of oxidative stress in general:
indeed, mPTP opening and aberrant mitochondrial depo-
larization were associated with significantly higher
mitochondrial superoxide generation.
The combined increase in ROS generation and depletion
of antioxidant defenses during IR results in oxidative
modification of biomolecules. Protein oxidation, which is
particularly damaging in the electron transport chain,
causes structural changes that impair mitochondrial respi-
ration and ATP synthesis [27]. IR neonatal cardiomyocytes
displayed elevated levels of 8-isoprostanes (an index of
lipoperoxidation) and a marked reduction in total antioxi-
dant capacity, consistent with the results we obtained in a
previous study [21]. Confocal microscope analysis
revealed high levels of mitochondrial superoxide following
reperfusion. Resv- and Trolox-treated IR cells were char-
acterized by a reduction in ROS production and in
isoprostane levels and by an increase in the overall anti-
oxidant defense system, demonstrating a strong protective
effect of these compounds. Interestingly, in our study, we
used Trolox and Resv at the same antioxidant capacity (as
assessed by luminometric assay (data not shown) to
determine whether the effects of these compounds were
simply a function of their antioxidant activity. Interest-
ingly, Resv proved to be more protective (as suggested by
the sharp reduction in oxidative stress markers, LDH
release and caspase activities) compared to Trolox, an
effect that is correlated with SIRT1 overexpression.
These findings agree with the reported Sirt1-induced
resistance to oxidative stress through FoxO in fibroblasts
[4]. In this study, overexpression of either Sirt1 or
constitutively active FoxO1a in cultured cardiac myocytes
stimulated expression of catalase, whereas upregulation of
catalase was inhibited in the presence of dominant negative
FoxO1a.
In our study, simulated IR caused strong impairment of
mitochondrial depolarization, which was restored by Resv
treatment and, to a lesser extent, by Trolox. We observed
similar effects when assessing mitochondrial permeability
transition pore opening, which was markedly affected by
IR and fully restored by Resv treatment only. All the above
protective effects against cellular injury induced by IR
were evident in Resv-treated IR ventricular myocytes,
which displayed a twofold increase in SIRT1 expression
compared to untreated IR cells.
In the presence of SIRT1 inhibitor, the protective effects
of Resv on IR-induced cell death parameters (particularly
caspase activity and LDH release) were completely abol-
ished, indicating a prominent role for SIRT1 in this
process.
These results agree with recent findings indicating that
Resv attenuates both steady-state and high glucose-induced
mitochondrial ROS production in cultured human coronary
arterial endothelial cells (CAECs). Similar effects, in the
same cells, were observed by SIRT1 overexpression, thus
mimicking Resv treatment and were attenuated by SIRT1
knockdown [28].
Our data clearly show that IR triggers necrotic cell
death. While Trolox treatment significantly slowed the rate
of necrosis, Resv exerted a more marked effect, high-
lighting the protective effect of SIRT1 overexpression also
in IR-induced necrosis. Interestingly, cells treated with
both Resv and a SIRT1 inhibitor displayed levels of cell
death fourfold higher than Resv-treated IR cardiomyocytes
and, however, higher than untreated IR cells.
Caspase-3 and caspase-9, which play a key role in
apoptotic cell death, displayed increased activity in ische-
mic cells following 1 h of reperfusion. Pre-treating cells
with Resv prior to ischemic challenge precluded this
increase. Treatment with Trolox, albeit to a lesser extent,
also promoted a significant reduction in apoptotic cell
death. The presence of SIRT1 inhibitor together with Resv
counteracted this reduction. In this case, caspase-3 and -9
activities did not differ significantly from IR cardiomyo-
cytes, suggesting that Resv may exert its anti-apoptotic
effects via SIRT1. The fact that SIRT1 inhibition abolished
the protective effects of Resv suggests that SIRT1 activa-
tion plays a fundamental role in Resv-induced cardiopro-
tection during IR.
Recently, several authors reported that sirtuins may play
a role in cardioprotection and cardiac hypertrophy. Phar-
macological studies have shown that SIRT1 overexpression
protects cardiomyocytes from serum deprivation-induced
death [12]. In contrast, sirtuin knockdown triggered cell
Fig. 8 a The phosphorylation and acetylation status of Akt immu-
noprecipitated from neonatal rat ventricular cardiomyocytes
determined by immunoblotting. b Western-blot analysis of ASK1
phosphorylation at Ser83 in neonatal rat ventricular cardiomyocytes.
Control normoxic cells (C), Resv (R), Trolox (T), SIRT1 inhibitor (I).
The reported values (mean ± SD) are representative of four inde-
pendent experiments, each performed in triplicate
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death in isolated neonatal rat cardiomyocytes [29]. It was
shown that Resv protects H9c2 cells from hypoxia-induced
apoptosis by signaling via the SIRT1-FOXO1 pathway
[15]. Moreover, SIRT1-induced upregulation of antioxi-
dants and downregulation of pro-apoptotic molecules, via
FOXO activation and reduction of oxidative stress,
protecting transgenic mice from IR-induced cardiac injury
[30].
Indeed, our findings suggest that SIRT1 expression is
upregulated by IR. Consistent with this, other authors
suggested that SIRT1 expression was upregulated by car-
diac stressors, including oxidative stress, aging, and heart
failure [4, 12], helping protect the heart from damage.
Together with previous evidence of its cardioprotective
role in the aging process and in oxidative stress [4], our
results suggest that stimulation of SIRT1 may represent a
novel approach to protect the heart from ischemic injury.
Indeed, our findings suggest that SIRT1 expression is
upregulated by IR. Consistent with this, SIRT1 expression
was also found to be upregulated by other cardiac stressors,
including oxidative stress, aging, and heart failure [4, 12],
helping protect the heart from damage. The regulation of
SIRT1 expression therefore appears stimulus-specific. In
animal models, Resv protects cardiac tissue from IR injury
[14]. Although Resv can stimulate both SIRT1 and SIRT3,
whether SIRT1 activation is brought about by direct
interaction between the two molecules, or via intermedi-
ates, remains to be determined [31]. Resv could also exert
its cardioprotective effects—such as its antioxidant role—
via SIRT1-independent mechanisms [32]. Our findings
suggest that SIRT1 overexpression protects against IR
injury. Importantly, Resv only promotes lifespan extension
when the SIR2 gene is present, having no effect when the
gene is deleted [33]. Resv treatment prevented IR-induced
cell death and enhanced SIRT1 activity, which was main-
tained post-IR. However, the fact that SIRT1 inhibition
abolished the protective effects of Resv suggests that
SIRT1 activation plays a fundamental role in Resv-induced
cardioprotection during IR.
A recent study by Hsu and colleagues found that SIRT1
upregulates the expression of cardioprotective molecules,
such as MnSOD, Trx1, and Bcl-xL, and at the same time
downregulates pro-apoptotic molecules, including Bax
[30]. SIRT1 is also known to deacetylate FOXO, leading to
upregulated expression of genes involved in cell-protective
processes [34]. Indeed, upregulation of MnSOD expression
by SIRT1 (as observed in cultured cardiomyocytes, for
example) seems tightly regulated by FOXO1.
In the cardiovascular system, Akt (protein kinase B)
plays critical roles in the regulation of cardiac hypertrophy,
angiogenesis, and apoptosis [35]. In cardiomyocytes, acti-
vation of the Akt pathway by insulin-like growth factor 1
(IGF-I) appears to be necessary for the anti-apoptotic
effects of IGF-I [36] and adenoviral expression of consti-
tutively active mutants of Akt reduces hypoxia-induced
apoptosis in vitro, while inhibition of Akt activity accel-
erated hypoxia-induced cardiomyocyte dysfunction [37].
Akt activity is also involved in ischemia/reperfusion-
induced myocardial injury and Akt activation accounts for
cardioprotection in rat heart [38–40].
Phosphorylation of residues Thr-308 and Ser-473 is
required for Akt activity [24, 41, 42]. Active Akt phos-
phorylates BAD, caspase-9, glycogen synthase kinase 3
(GSK-3), ASK1, fork-head transcription factors, and
thereby induces antiapoptotic effects [24, 41].
Deacetylation of lysine residues by histone deacetylases
is a posttranslational mechanism that controls the activity
of many cellular proteins, including kinases [43, 44].
SIRT1 regulates many of the same cellular processes reg-
ulated by Akt [44], and SIRT1 activators have been used to
treat metabolic disorders characterized by defective Akt
signaling [45]. A recent study of Sundaresan and cowork-
ers [46] demonstrated that Akt deacetylation by SIRT1 is a
necessary mechanism for its activation. Here, we confirm
that SIRT1 promotes Akt activation in our cellular model
and protects cardiomyocytes from IR-induced cell death.
Apoptosis signal-regulating kinase 1 (ASK1) represents
a mitogen-activated protein kinase kinase kinase family
member that acts upstream of JNK and p38 kinases [22,
23]. A number of studies have shown that ASK1 is acti-
vated by a variety of stress-related stimuli, including serum
withdrawal, ROS, TNF-a, and IR [47, 48]. Phosphorylation
of ASK1 at Ser-83 (a specific Akt phosphorylation site) is
correlated with the decreased activity of ASK1. It has been
shown that Akt can phosphorylate ASK1 at Ser-83 to
maintain ASK1 in an inactive form, however, Thr-845 is an
autophosphorylation site that is critical for ASK1 activa-
tion [24, 49].
In our present study, we examined the activity of ASK1
in IR. As shown in Fig. 8, we found that the phosphory-
lation of ASK1 at Ser-83 was diminished and at the same
time, the phosphorylation of JNK and p38 dramatically
increased. It has been reported that H2O2 can induce the
decreased phosphorylation of Akt and ASK1 (Ser-83),
while the phosphorylation of ASK1 at Thr-845 was
increased. Akt, however, had little effect on the H2O2
responsiveness of the ASK1 point mutant, ASK1S83A,
suggesting a specific phosphorylation event in Akt-medi-
ated inhibition [42]. Our findings indicate that ASK1 is
activated in response to IR and Resv treatment increased
ASK1 phosphorylation at Ser-83 to control levels.
Myocyte apoptosis is induced during reperfusion by
activating pro-injurious kinases, including p38-mitogen-
activated protein kinase (MAPK) and c-jun NH2-terminal
kinase (JNK) [50] whose induction by physical, chemical,
and physiological stressors [3] is well documented.
M. Becatti et al.
123
In contrast, cardioprotection is afforded by activating
extracellular regulated kinase (ERK1/2) and AKT [51, 52].
In this study, the effect of SIRT1 overexpression in relation
to MAPK signaling in IR ventricular myocytes was
examined. JNK, ERK-1/2, and p38 kinases showed
opposing regulatory effects on apoptosis. Using specific
inhibitors for each MAPK sub-type, we demonstrated that
JNK and p38 kinases exerted pro-apoptotic effects,
whereas ERK was anti-apoptotic and therefore protected
against IR-induced apoptosis. Numerous studies have
shown that activation of ERK signaling by various stimuli
has a cardioprotective effect during reperfusion [51].
Huang and colleagues found that both SIRT1 transfection
and treatment with Resv promotes ERK phosphorylation
(Thr202/Tyr204) in human fibroblasts [53]. While the
mechanism of SIRT1-induced ERK phosphorylation
remains to be elucidated, Kobayashi et al. reported that the
HDAC inhibitor suppressed MAPK signaling by upregu-
lating Rap1 expression [54], suggesting that SIRT1 may
stimulate ERK signaling in a similar way. In our cell
model, simulated IR caused a dramatic decrease in the
p-ERK/total ERK ratio, which was only reversed by
treatment with Resv. To further investigate the molecular
pathways underlying the protective effects induced by
Resv in IR cardiomyocytes, caspase-3 activity and LDH
release were analyzed in the presence of specific MAPK
inhibitors. Interestingly, IR cells displayed the highest
caspase-3 activity in the presence of ERK inhibitor, an
effect that was suppressed by Resv treatment, indicating a
prominent role for SIRT1 in protection against apoptotic
cell death. SIRT1 overexpression was associated with
enhancement of ERK signaling after IR, while incubation
with ERK inhibitor decreased the protective effect of
SIRT1 overexpression, suggesting that ERK signaling in
part underlies SIRT1-mediated protection.
The role that JNK plays in IR is still a matter of debate.
A number of in vitro and in vivo studies have shown that
JNK is activated by reoxygenation [55–57]. There is little
evidence of JNK activation during the ischemic phase,
although some studies suggest it does occur [58]. Whether
stress-induced JNK signaling has a protective or patho-
logical effect depends on the cell type, a dichotomy that is
apparent in cardiomyocytes. Treatment with JNK-specific
inhibitors reduces infarct size and apoptotic cell death
following IR [59, 60]. JNK activity also exacerbates
the deleterious effects of several proteins involved in
IR-induced myocardial injury [60–62]. Moreover, JNK is
thought to associate with mitochondria, possibly via
interactions with pro-apoptotic proteins [62], while it also
regulates nuclear translocation of the mitochondrial apop-
tosis-inducing factor (AIF) [61, 63]. In other studies
performed in cardiac myocytes, inhibition of JNK activity
promoted apoptosis and stimulated caspase-3 [64] and
caspase-9 [65] activity in an in vitro IR model. It has also
been suggested that the cardioprotective effect of JNK may
be partly due to Akt activation, a key pro-survival protein
in post-ischemic cardiomyocytes [66]. The role of JNK
signaling in IR thus remains unclear, possibly due to the
complexity of the multistage, interconnected signaling
cascades that underlie this process.
In our experimental model, simulated IR triggered an
increase in the phospho-JNK/total JNK ratio, with Resv
treatment reducing JNK phosphorylation to control levels.
Treatment with Trolox or SIRT1 inhibitor, however, did not
reduce JNK phosphorylation. Levels of apoptotic cell death
were found to be significantly lower in the presence of JNK
inhibitor, suggesting a role for these pathways in IR-
induced cell death. Cao and coworkers [67] reported that
SIRT1 knockdown (using siRNA) in cultured skin kerati-
nocytes stimulates UV-induced JNK activation, an effect
that is inhibited by Resv, all of which suggests that SIRT1
precludes JNK activation by UV light. The same group also
found that SIRT1 negatively regulates UV-induced JNK
activation. This mechanism, which likely proceeds via
deacetylation and inhibition of one or several upstream JNK
signals, may exist to further protect against UV-induced
cell death. Further work is required to determine the
mechanism by which SIRT1 negatively regulates JNK
activation, however, our findings shed further light on the
anti-apoptotic function of SIRT1 activation. Disagreeing
results have been obtained by Nasrin and coworkers, who
found that JNK1 modifies the function of SIRT1, stimu-
lating its activity and altering its localization [68]. Indeed,
our data on the whole suggest an important role for JNK in
IR-induced cell death and for SIRT1 in JNK inhibition.
Our findings shed further light on how SIRT1may regulate
cell survival under conditions of oxidative stress. As a cell
survival factor, SIRT1 may promote resistance to oxidative
stress in mammalian cells. For example, SIRT1 overexpres-
sion in normal human IMR-90 fibroblasts reduced H2O2-
induced apoptosis [69]. Similarly, HEK293T cells treated
with serum from calorie-restricted rats displayed increased
SIRT1 expression and concomitant inhibition of Bax-medi-
ated apoptosis [70]. Kume et al. [71] showed that SIRT1
overexpression in mesangial cells decreases H2O2-induced
acetylation of p53. Moreover, neither SIRT1 overexpression
nor its knockdown had any effect on H2O2-mediated phos-
phorylation of MAPKs.
The role of p38 during IR is well documented, although
reports are conflicting as to its precise effect, with different
lines of evidence pointing to protective or deleterious roles
for p38. Marked activation of p38 was observed in isolated,
perfused rat hearts [72], with several studies showing that
p38 activation during ischemia promotes injury [73, 74].
Equally, numerous studies have also demonstrated a pro-
tective role for p38 during ischemia [75–77]. In our cell
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model, simulated IR triggered an increase in the phospho-
p38/total p38 ratio, with Resv treatment reducing p38
phosphorylation to control levels. In the presence of p38
inhibitor, we observed a significant reduction in apoptosis,
suggesting a role for these pathways in IR-induced cell
death. The exact contribution of p38 kinase to ischemic
injury and protection is determined by the isoforms and
upstream/downstream pathways involved, as well as the
level, duration, mode, and timing of induction. Identifying
the beneficial versus deleterious aspects of p38 signaling is
a major issue that must be addressed by future studies.
In summary, our data show a cardioprotective role for
SIRT1 in IR. During IR, SIRT1 stimulates the expression
of cardioprotective molecules while downregulating levels
of pro-apoptotic molecules, thereby reducing oxidative
stress and inhibiting apoptosis. Our findings also shed
further light on the molecular mechanisms by which SIRT1
modulates MAPK signaling via the Akt-ASK1 signaling.
SIRT1 activation may therefore represent a novel
approach to protect the heart from ischemic injury.
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